Song Seo Woo, Kim Su Deok, Oh Dong Yoon, Lee Yongju, Lee Amos Chungwon, Jeong Yunjin, Bae Hyung Jong, Lee Daewon, Lee Sumin, Kim Jiyun, Kwon Sunghoon
Department of Electrical and Computer Engineering Seoul National University Seoul 08826 South Korea.
Institutes of Entrepreneurial BioConvergence Seoul National University Seoul 08826 South Korea.
Adv Sci (Weinh). 2018 Nov 20;6(3):1801380. doi: 10.1002/advs.201801380. eCollection 2019 Feb 6.
Large-scale screening of sequential drug combinations, wherein the dynamic rewiring of intracellular pathways leads to promising therapeutic effects and improvements in quality of life, is essential for personalized medicine to ensure realistic cost and time requirements and less sample consumption. However, the large-scale screening requires expensive and complicated liquid handling systems for automation and therefore lowers the accessibility to clinicians or biologists, limiting the full potential of sequential drug combinations in clinical applications and academic investigations. Here, a miniaturized platform for high-throughput combinatorial drug screening that is "pipetting-free" and scalable for the screening of sequential drug combinations is presented. The platform uses parallel and bottom-up formation of a heterogeneous drug-releasing hydrogel microarray by self-assembly of drug-laden hydrogel microparticles. This approach eliminates the need for liquid handling systems and time-consuming operation in high-throughput large-scale screening. In addition, the serial replacement of the drug-releasing microarray-on-a-chip facilitates different drug exchange in each and every microwell in a simple and highly parallel manner, supporting scalable implementation of multistep combinatorial screening. The proposed strategy can be applied to various forms of combinatorial drug screening with limited amounts of samples and resources, which will broaden the use of the large-scale screening for precision medicine.
对序贯药物组合进行大规模筛选至关重要,因为细胞内信号通路的动态重连可带来有前景的治疗效果并改善生活质量,这对于个性化医疗以确保符合实际的成本和时间要求以及减少样本消耗而言必不可少。然而,大规模筛选需要昂贵且复杂的液体处理系统来实现自动化,因此降低了临床医生或生物学家的可及性,限制了序贯药物组合在临床应用和学术研究中的全部潜力。在此,我们展示了一种用于高通量组合药物筛选的小型化平台,该平台 “无需移液” 且可扩展用于序贯药物组合的筛选。该平台通过载药水凝胶微粒的自组装,以并行和自下而上的方式形成异质药物释放水凝胶微阵列。这种方法消除了高通量大规模筛选中对液体处理系统的需求以及耗时的操作。此外,芯片上药物释放微阵列的连续替换以简单且高度并行的方式促进了每个微孔中不同药物的交换,支持多步组合筛选的可扩展实施。所提出的策略可应用于各种形式的有限样本量和资源的组合药物筛选,这将拓宽大规模筛选在精准医学中的应用。